(Reuters) -A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and a type of liver disease, a study funded by the National Institutes of Health showed on Tuesday.
Semaglutide is the active ingredient in Novo Nordisk’s popular weightloss drug Wegovy and diabetes treatment Ozempic.
This is the first clinical trial of semaglutide for the type of liver disease in people with HIV.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, is characterized by the accumulation of excess fat in the liver that is not caused by alcohol consumption or viral hepatitis.
(Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri)
Comments